Responses
Regular and young investigator award abstracts
Clinical trials in progress
404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
